These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

662 related articles for article (PubMed ID: 26331539)

  • 1. Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists.
    Prost S; Relouzat F; Spentchian M; Ouzegdouh Y; Saliba J; Massonnet G; Beressi JP; Verhoeyen E; Raggueneau V; Maneglier B; Castaigne S; Chomienne C; Chrétien S; Rousselot P; Leboulch P
    Nature; 2015 Sep; 525(7569):380-3. PubMed ID: 26331539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PPARγ: Welcoming the New Kid on the CML Stem Cell Block.
    Apsel Winger B; Shah NP
    Cancer Cell; 2015 Oct; 28(4):409-411. PubMed ID: 26461088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PPARγ ligands increase antileukemic activity of second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia cells.
    Glodkowska-Mrowka E; Manda-Handzlik A; Stelmaszczyk-Emmel A; Seferynska I; Stoklosa T; Przybylski J; Mrowka P
    Blood Cancer J; 2016 Jan; 6(1):e377. PubMed ID: 26745851
    [No Abstract]   [Full Text] [Related]  

  • 4. Haematological cancer: Repositioned to attack CML cells.
    Killock D
    Nat Rev Clin Oncol; 2015 Nov; 12(11):624. PubMed ID: 26391777
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.
    Chen M; Gallipoli P; DeGeer D; Sloma I; Forrest DL; Chan M; Lai D; Jorgensen H; Ringrose A; Wang HM; Lambie K; Nakamoto H; Saw KM; Turhan A; Arlinghaus R; Paul J; Stobo J; Barnett MJ; Eaves A; Eaves CJ; Holyoake TL; Jiang X
    J Natl Cancer Inst; 2013 Mar; 105(6):405-23. PubMed ID: 23446755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.
    Lin H; Chen M; Rothe K; Lorenzi MV; Woolfson A; Jiang X
    Oncotarget; 2014 Sep; 5(18):8637-50. PubMed ID: 25226617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer: Repositioned to kill stem cells.
    Holyoake T; Vetrie D
    Nature; 2015 Sep; 525(7569):328-9. PubMed ID: 26331538
    [No Abstract]   [Full Text] [Related]  

  • 8. The implication of cancer progenitor cells and the role of epigenetics in the development of novel therapeutic strategies for chronic myeloid leukemia.
    Tortorella SM; Hung A; Karagiannis TC
    Antioxid Redox Signal; 2015 Jun; 22(16):1425-62. PubMed ID: 25366930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of cancer stem cells in chronic myeloid leukaemia.
    Jørgensen HG; Holyoake TL
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of autophagy by BCR/ABL.
    Calabretta B; Salomoni P
    Front Biosci (Schol Ed); 2012 Jan; 4(2):453-60. PubMed ID: 22202070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?
    Goldman J; Gordon M
    Leuk Lymphoma; 2006 Jan; 47(1):1-7. PubMed ID: 16321820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tyrosine kinase inhibitors for the treatment of CML].
    Heim D
    Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition.
    Ng KP; Manjeri A; Lee KL; Huang W; Tan SY; Chuah CT; Poellinger L; Ong ST
    Blood; 2014 May; 123(21):3316-26. PubMed ID: 24705490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
    Aljedai A; Buckle AM; Hiwarkar P; Syed F
    PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.
    Corbin AS; Agarwal A; Loriaux M; Cortes J; Deininger MW; Druker BJ
    J Clin Invest; 2011 Jan; 121(1):396-409. PubMed ID: 21157039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tyrosine kinase inhibitors in the therapy of chronic myeloid leukaemia].
    Grzybowska-Izydorczyk O; Góra-Tybor J; Robak T
    Postepy Hig Med Dosw (Online); 2006; 60():490-7. PubMed ID: 17013368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
    Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J
    J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual PPARalpha/gamma ligand TZD18 either alone or in combination with imatinib inhibits proliferation and induces apoptosis of human CML cell lines.
    Zang C; Liu H; Waechter M; Eucker J; Bertz J; Possinger K; Koeffler HP; Elstner E
    Cell Cycle; 2006 Oct; 5(19):2237-43. PubMed ID: 17102607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Research advance on molecular genetics of CML blast crisis].
    Zhu HQ; Zhang S; Liu XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of γ-catenin inhibits CML cell growth and potentiates the response of CML cells to imatinib through β-catenin inhibition.
    Niu CC; Zhao C; Yang ZD; Zhang XL; Wu WR; Pan J; Zhao C; Li ZQ; Ding W; Yang Z; Si WK
    Int J Mol Med; 2013 Feb; 31(2):453-8. PubMed ID: 23233089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.